Adaptive Phage Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
66
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$15.9M
Adaptive Phage Therapeutics General Information
Description
Operator of a clinical-stage company intended to treat multi-drug resistant pathogenic bacteria. The company provides services by using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.
Contact Information
Website
www.aphage.comCorporate Office
- 708 Quince Orchard Road
- Suite 205
- Gaithersburg, MD 20878
- United States
Corporate Office
- 708 Quince Orchard Road
- Suite 205
- Gaithersburg, MD 20878
- United States
Adaptive Phage Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 15-Mar-2024 | $15.9M | Completed | Clinical Trials - Phase 2 | ||
| 9. Later Stage VC (Series B1) | 09-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series B) | 04-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 30-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 16-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 17-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 20-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Debt - PPP | 15-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 2. Debt - General | $3.1M | $5.3M | Completed | Pre-Clinical Trials | ||
| 1. Early Stage VC (Series AA) | 30-Nov-2017 | $2.2M | $2.2M | Completed | Pre-Clinical Trials |
Adaptive Phage Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series AA | 2,217,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 1.9% |
Adaptive Phage Therapeutics Comparisons
Industry
Financing
Details
Adaptive Phage Therapeutics Competitors (18)
One of Adaptive Phage Therapeutics’s 18 competitors is Eligo Bioscience, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Locus Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Intralytix | Corporate Backed or Acquired | Baltimore, MD | ||||
| BiomX | Formerly VC-backed | Gaithersburg, MD | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA |
Adaptive Phage Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adaptive Phage Therapeutics Patents
Adaptive Phage Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3231482-A1 | Phage dispensing system | Pending | 13-Sep-2021 | ||
| CA-3221242-A1 | Improved anti-biofilm assay methods | Pending | 08-Jun-2021 | ||
| AU-2022290516-A1 | Improved anti-biofilm assay methods | Pending | 08-Jun-2021 | ||
| EP-4352245-A1 | Improved anti-biofilm assay methods | Inactive | 08-Jun-2021 | ||
| JP-2024521574-A | Improved anti-biofilm assay method | Pending | 08-Jun-2021 | C12Q1/18 |
Adaptive Phage Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adaptive Phage Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AMR Action Fund | Impact Investing | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Hackensack Meridian Health | Corporation | Minority | ||
| Mayo Clinic | Corporation | Minority |
Adaptive Phage Therapeutics FAQs
-
When was Adaptive Phage Therapeutics founded?
Adaptive Phage Therapeutics was founded in 2016.
-
Where is Adaptive Phage Therapeutics headquartered?
Adaptive Phage Therapeutics is headquartered in Gaithersburg, MD.
-
What is the size of Adaptive Phage Therapeutics?
Adaptive Phage Therapeutics has 66 total employees.
-
What industry is Adaptive Phage Therapeutics in?
Adaptive Phage Therapeutics’s primary industry is Drug Discovery.
-
Is Adaptive Phage Therapeutics a private or public company?
Adaptive Phage Therapeutics is a Private company.
-
What is the current valuation of Adaptive Phage Therapeutics?
The current valuation of Adaptive Phage Therapeutics is .
-
What is Adaptive Phage Therapeutics’s current revenue?
The current revenue for Adaptive Phage Therapeutics is .
-
How much funding has Adaptive Phage Therapeutics raised over time?
Adaptive Phage Therapeutics has raised $78.3M.
-
Who are Adaptive Phage Therapeutics’s investors?
AMR Action Fund, Alexandria Venture Investments, Deerfield Management, Hackensack Meridian Health, and Mayo Clinic are 5 of 9 investors who have invested in Adaptive Phage Therapeutics.
-
Who are Adaptive Phage Therapeutics’s competitors?
Eligo Bioscience, Locus Biosciences, Intralytix, BiomX, and Seres Therapeutics are some of the 18 competitors of Adaptive Phage Therapeutics.
-
When was Adaptive Phage Therapeutics acquired?
Adaptive Phage Therapeutics was acquired on 15-Mar-2024.
-
Who acquired Adaptive Phage Therapeutics?
Adaptive Phage Therapeutics was acquired by BiomX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
